Cellular models for the screening and development of anti-hepatitis C virus agents.
Investigations on the biology of hepatitis C virus (HCV) have been hampered by the lack of small animal models. Efforts have therefore been directed to designing practical and robust cellular models of human origin able to support HCV replication and production in a reproducible, reliable and consistent manner. Many different models based on different forms of virions and hepatoma or other cell types have been described including virus-like particles, pseudotyped particles, subgenomic and full length replicons, virion productive replicons, immortalised hepatocytes, fetal and adult primary human hepatocytes. This review focuses on these different cellular models, their advantages and disadvantages at the biological and experimental levels, and their respective use for evaluating the effect of antiviral molecules on different steps of HCV biology including virus entry, replication, particles generation and excretion, as well as on the modulation by the virus of the host cell response to infection.
Gondeau
Claire
C
Inserm, U632, Université Montpellier1, UMR-S632, Montpellier, F-34293 France.
Pichard-Garcia
Lydiane
L
Maurel
Patrick
P
D000998:Antiviral Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004705:Endocytosis; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics / Q000276:immunology / Q000502:physiology; D022781:Hepatocytes / Q000821:virology; D006801:Humans; D034622:RNA Interference; D012367:RNA, Viral / Q000096:biosynthesis; D014761:Viral Hepatitis Vaccines / Q000276:immunology; D014771:Virion / Q000502:physiology; D014779:Virus Replication
D000998:Antiviral Agents; D012367:RNA, Viral; D014761:Viral Hepatitis Vaccines